When Validation Becomes the Bottleneck
Why Large Capital Projects Need a Different Operating Model In large pharmaceutical capital projects, speed is always a priority. But one part of the process
Blog
QMSR 2026 – When “Having a QMS” Is no longer enough
For years, the question was simple. Do you have a Quality Management System? Procedures written. Deviations logged. CAPAs opened, closed, archived. Everything in place. Then,
Annex 1 is not a checklist
Annex 1 is not a checklist… It’s a system of decisions, and the CCS is its backbone. For years, compliance in sterile manufacturing was often
A Complete Guide to Equipment FAT in GMP and Pharma Projects
Once the 3D model is approved, the project leaves the digital world and steps into the real one. What used to exist only on a
A Complete Guide to Effective 3D Model Reviews in GMP and Pharma Projects
Before any pipe is welded or any skid is built, every project begins in the same place: the model room. It’s that moment when ideas
Designing a pharmaceutical facility is like designing a kitchen… Here’s Why
The kitchen Story “A pharmaceutical plant is just like a big kitchen. Our role is to help the client decide what they want to cook,
Audit Readiness Is Not a Training, It’s a Culture
If there is one truth shared across every inspection, whether in the US, Europe, or Asia-Pacific, it’s this: Audit readiness doesn’t depend on how well
AI in the Pharmaceutical Industry: Validating to Ensure Quality—and Patient Safety
Conversations That Matter No deviation’s Takeaways from 2025 ISPE France Conference – Validation of AI in the pharmaceutical industry. Presentation of the approach currently being
From Uncertainty to Reality: Validating AI and Gen AI in the Pharmaceutical Industry
Conversations That Matter No deviation’s Takeaways from 2025 ISPE France Conference – Validation of AI in the pharmaceutical industry. Presentation of a validation strategy for
Harmonisation of Global Standards with China’s (NMPA) Regulatory Landscape
With No deviation now established in China, we’re taking a closer look at China’s regulatory landscape and its global connections. Understanding how the NMPA (National
